About InFo Diabetologie

InFo Diabetologie

InFo Diabetologie is the German interdisciplinary specialist journal for practical and scientific diabetology, published by Springer Medizin for the physicians confronting the diabetes epidemic. Focused on prevention, diagnosis, and therapy, the journal offers the current research results, data, facts, and trends from the diabetology, reported and commented by the specialists from the practice, the clinic, and the science for the physicians who need the applicable knowledge. With its Journal Screen, its CME training with high practice relevance, and its congress highlights, it serves the physicians treating the diabetes mellitus in its growing prevalence and complexity.

Overview

InFo Diabetologie appears as the diabetology's information journal: the medium for the diabetologically active physicians in the practice and the clinic, and the internists and general practitioners with the diabetological focus interest who treat the growing patient numbers. The editorial program is interdisciplinary by design: the contributions from all relevant specialties, from the endocrinology to the cardiology to the nephrology; the new trends and developments presented from the various perspectives, showing the diabetes' systemic nature; and the future prospects discussed, from the therapeutic innovations to the care models. The contents include the Journal Screen with the interdisciplinary contributions, the CME continuing education with the high practice relevance that the busy physicians can apply, the current reports with the pointed highlights of the international congresses, the case reports illustrating the practice, and the Politik & Praxis with the news from the specialist organizations in cooperation with the Berufsverband der Niedergelassenen Diabetologen in Bayern (BNDB).

The journal's scientific standing is documented by the indexing: listed in the Science Citation Index Expanded and Scopus, the databases that define the citable medical literature. The volumes 3/2009 through 19/2025 document the continuous publication: the journal that has informed the diabetology for over 15 years.

History

InFo Diabetologie was founded by Dr. Dirk Einecke during his tenure at the Münchner Medizinische Wochenschrift (MMW): the medical journalist, later the publisher of the Springer Medizin umbrella brand, created the new title alongside CardioVasc. The founding recognized the diabetology's rapid knowledge growth: the continuously advancing insights required the continuous education that the journal provides.

The journal's development tracked the diabetology's revolutions: the new drug classes from the GLP-1 agonists to the SGLT2 inhibitors, the continuous glucose monitoring's spread, and the technology's advance from the pens to the pumps to the closed loops. Each wave created the information need that the journal fills: the research results reported, the data presented, and the trends commented by the experts.

Coverage and Content

The therapy coverage addresses the diabetology's pharmacological revolution: the GLP-1 receptor agonists, the SGLT2 inhibitors, and the combination therapies, with the study data and the practice guidance. The technology coverage follows the digitalization: the continuous glucose monitoring (CGM) proving worthwhile even in the type-2 diabetes, the insulin pumps, and the automated insulin delivery. The interdisciplinary coverage addresses the diabetes' complications: the cardiovascular, the renal, and the ophthalmological, and the special situations like the diabetes mellitus under the cancer immunotherapy.

The Journal Screen presents the interdisciplinary contributions from all relevant fields: the research results referiert and commented by the specialists. The CME modules provide the certified education with the high practice relevance. The congress reports deliver the pointed highlights of the international meetings: the DDG, the EASD, and the ADA. The Politik & Praxis covers the profession's news: the BNDB's activities and the health-policy developments.

The Therapeutic Revolution

The diabetology's therapeutic revolution, which InFo Diabetologie chronicles, is among the medicine's most dramatic: the GLP-1 receptor agonists, originally the diabetes drugs, became the weight-loss sensation transforming the obesity treatment; the SGLT2 inhibitors, originally the glucose-lowering agents, became the heart-failure and kidney-disease therapies; and the continuous glucose monitoring, originally the type-1 diabetes tool, proved worthwhile in the type-2 diabetes. The journal reports these revolutions as they happen: the study data, the guideline updates, and the practice implications.

The revolution's breadth requires the interdisciplinary journal: the cardiologists prescribe the SGLT2 inhibitors for the heart failure, the nephrologists for the kidney disease, and the diabetologists coordinate the complex patients. The InFo Diabetologie's Journal Screen brings these perspectives together: the contributions from all relevant specialties, reported and commented by the experts. The special situations, like the diabetes mellitus under the cancer immunotherapy with its abrupt insulin deficiency and ketoacidosis, show the diabetology's expanding frontier: the journal covers what the textbooks haven't caught. In the therapeutic revolution, the journal is the chronicle: the medium that keeps the physicians current with the drugs and technologies transforming their patients' lives.

The Diabetes Epidemic

InFo Diabetologie serves the medicine's response to the diabetes epidemic: the millions of Germans with the diabetes mellitus, the growing prevalence driven by the demographics and the lifestyle, and the enormous health-economic burden. The journal's prevention, diagnosis, and therapy focus addresses the full spectrum: from the prediabetes's lifestyle intervention to the established diabetes's complex management.

The diabetology's rapid advance makes the journal essential: the physicians treating the diabetes must follow the new drugs, the new technologies, and the new guidelines, and the InFo Diabetologie curates this knowledge. The interdisciplinary approach reflects the diabetes' systemic nature: the diabetologist coordinates the cardiologist, the nephrologist, and the ophthalmologist, and the journal brings their perspectives together.

Organization and Ownership

InFo Diabetologie is published by the Springer Medizin Verlag GmbH, part of the Springer Nature group. The journal's bibliographic data: Print ISSN 1865-5459, electronic ISSN 2196-6362, journal ID 15034. The editorial details beyond the publisher are not publicly confirmed in the available sources.

The business model is the medical-publishing model: the subscriptions from the physicians and the institutions who need the continuous diabetology education, and the advertising from the pharmaceutical industry's diabetes manufacturers, from the GLP-1 producers to the CGM makers to the insulin companies. The indexing in the Science Citation Index Expanded and Scopus supports the scientific authors' publication incentives: the researchers publish in the journal that counts. The journal's 15-year continuity, from the volume 3/2009 to the 19/2025, documents the sustained demand: the diabetology's rapid advance creates the permanent education need that the InFo Diabetologie fills, issue after issue, year after year.

Digital Presence

The springermedizin.de portal carries the journal digitally: the articles, the CME modules, and the archive, with the current 2026 issues accessible online for the subscribers and the interested physicians. The link.springer.com platform provides the citable articles with the DOIs: the journal integrated into the scientific literature. The digital formats extend the print: the physicians access the research results, complete the CME online, and follow the congress highlights on the devices.

For the physicians treating the diabetes, InFo Diabetologie is the information journal: the interdisciplinary medium with the current research results, the data, the facts, and the trends, reported and commented by the specialists from the practice, the clinic, and the science; the CME training with the high practice relevance; and the congress highlights from the international meetings. In the era of the diabetes epidemic and the therapeutic revolution, when the new drugs and technologies transform the patients' prospects, the journal keeps the physicians current: the prevention, the diagnosis, and the therapy, for the patients whose lives depend on the good diabetes care, every single day, in every practice, without exception.